Literature DB >> 26013988

Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma.

Thuy B Tran1, Motaz Qadan1, Monica M Dua1, Jeffrey A Norton1, George A Poultsides1, Brendan C Visser2.   

Abstract

BACKGROUND: Nodal metastasis is a known prognostic factor for small bowel adenocarcinoma. The goals of this study were to evaluate the number of lymph nodes (LNs) that should be retrieved and the impact of lymph node ratio (LNR) on survival.
METHODS: Surveillance, Epidemiology, and End Results was queried to identify patients with small bowel adenocarcinoma who underwent resection from 1988 to 2010. Survival was calculated with the Kaplan-Meier method. Multivariate analysis identified predictors of survival.
RESULTS: A total of 2,772 patients underwent resection with at least one node retrieved, and this sample included equal numbers of duodenal (n = 1,387) and jejunoileal (n = 1,386) adenocarcinomas. There were 1,371 patients with no nodal metastasis (N0, 49.4%), 928 N1 (33.5%), and 474 N2 (17.1%). The median numbers of LNs examined for duodenal and jejunoileal cancers were 9 and 8, respectively. Cut-point analysis demonstrated that harvesting at least 9 for jejunoileal and 5 LN for duodenal cancers resulted in the greatest survival difference. Increasing LNR at both sites was associated with decreased overall median survival (LNR = 0, 71 months; LNR 0-0.02, 35 months; LNR 0.21-0.4, 25 months; and LNR >0.4, 16 months; P < .001). Multivariate analysis confirmed number of LNs examined, T-stage, LN positivity, and LNR were independent predictors of survival.
CONCLUSION: LNR has a profound impact on survival in patients with small bowel adenocarcinoma. To achieve adequate staging, we recommend retrieving a minimum of 5 LN for duodenal and 9 LN for jejunoileal adenocarcinomas.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26013988     DOI: 10.1016/j.surg.2015.03.048

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  An Examination of Lymph Node Sampling as a Predictor of Survival in Resected Node-Negative Small Bowel Adenocarcinoma: a SEER Database Analysis.

Authors:  Maclean Thiessen; R M Lee-Ying; J G Monzon; P A Tang
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

Authors:  Emanuela Dell'Aquila; Tea Zeppola; Marco Stellato; Francesco Pantano; Mario Scartozzi; Cristina Madaudo; Filippo Pietrantonio; Chiara Cremolini; Giuseppe Aprile; Bruno Vincenzi; Roberto Moretto; Marco Puzzoni; Silvio Ken Garattini; Riccardo Lobefaro; Giuseppe Tonini; Daniele Santini
Journal:  Clin Med Insights Oncol       Date:  2020-08-04

Review 3.  Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management.

Authors:  Fabio Gelsomino; Rita Balsano; Stefania De Lorenzo; Ingrid Garajová
Journal:  Curr Oncol       Date:  2022-02-17       Impact factor: 3.677

Review 4.  Duodenal adenocarcinoma: Advances in diagnosis and surgical management.

Authors:  Jordan M Cloyd; Elizabeth George; Brendan C Visser
Journal:  World J Gastrointest Surg       Date:  2016-03-27

5.  Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location?

Authors:  Hani Oweira; Omar Abdel-Rahman; Arianeb Mehrabi; Christoph Reissfelder
Journal:  J Gastrointest Oncol       Date:  2019-06

6.  Prognostic Value of Lymph Node Evaluation in Stage II Small Bowel Adenocarcinoma: An Updated Analysis of Surveillance, Epidemiology, and End Results Database.

Authors:  Zhen Liu; Kun Liu; Jiale Gao; Chao Jing; Yanhong Ma; Shu Zheng; Jianzhen Shan
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

Review 7.  Artificial intelligence in small intestinal diseases: Application and prospects.

Authors:  Yu Yang; Yu-Xuan Li; Ren-Qi Yao; Xiao-Hui Du; Chao Ren
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

8.  A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma.

Authors:  Na Wang; Jin Yang; Jun Lyu; Qingqing Liu; Hairong He; Jie Liu; Li Li; Xuequn Ren; Zhendong Li
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430

9.  Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study.

Authors:  Zi-Hao Dai; Qi-Wen Wang; Qing-Wei Zhang; Xia-Lin Yan; Thomas Aparicio; Yang-Yang Zhou; Huan Wang; Chi-Hao Zhang; Aziz Zaanan; Pauline Afchain; Yan Zhang; Hui-Min Chen; Yun-Jie Gao; Zhi-Zheng Ge
Journal:  EBioMedicine       Date:  2020-09-24       Impact factor: 8.143

10.  Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas.

Authors:  Alessandro Vanoli; Federica Grillo; Camilla Guerini; Giuseppe Neri; Giovanni Arpa; Catherine Klersy; Gabriella Nesi; Paolo Giuffrida; Gianluca Sampietro; Sandro Ardizzone; Paolo Fociani; Roberto Fiocca; Giovanni Latella; Fausto Sessa; Antonietta D'Errico; Deborah Malvi; Claudia Mescoli; Massimo Rugge; Stefano Ferrero; Gilberto Poggioli; Fernando Rizzello; Maria C Macciomei; Donatella Santini; Umberto Volta; Roberto De Giorgio; Giacomo Caio; Antonio Calabrò; Carolina Ciacci; Maria D'Armiento; Aroldo Rizzo; Gaspare Solina; Michele Martino; Francesco Tonelli; Vincenzo Villanacci; Renato Cannizzaro; Vincenzo Canzonieri; Ada Maria Florena; Livia Biancone; Giovanni Monteleone; Roberto Caronna; Antonio Ciardi; Luca Elli; Flavio Caprioli; Maurizio Vecchi; Renata D'Incà; Fabiana Zingone; Anna D'Odorico; Marco Vincenzo Lenti; Barbara Oreggia; Luca Reggiani Bonetti; Antonino Giulio Giannone; Augusto Orlandi; Valeria Barresi; Rachele Ciccocioppo; Giuseppe Amodeo; Elena Biletta; Ombretta Luinetti; Paolo Pedrazzoli; Andrea Pietrabissa; Gino Roberto Corazza; Enrico Solcia; Marco Paulli; Antonio Di Sabatino
Journal:  Ann Surg Oncol       Date:  2020-08-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.